Revolution Medicines (RVMD) GC Jeff Cislini Sells Shares, Exercises Options

What Happened

• Jeff Cislini, General Counsel of Revolution Medicines (RVMD), exercised options and sold common stock on August 21, 2026. He exercised 29,680 shares at $18.56 (cost $550,861) and 26,600 shares at $21.61 (cost $574,826), and sold multiple open‑market tranches totaling about $11.9 million in proceeds.
• Sale details recorded in the filing: 3,400 shares at a weighted avg $207.24 ($704,603), 17,323 at $208.37 ($3,609,573), 25,817 at $209.25 ($5,402,200), 2,540 at $210.26 ($534,072), 4,500 at $211.34 ($951,038), and 3,314 at $212.06 ($702,761). The filing also records the exercised derivatives separately at $0 (reflecting conversion/exercise entries).

Key Details

• Transaction date: August 21, 2026; Form 4 filed August 25, 2026 (timely filing).
• Options exercised: 29,680 @ $18.56 and 26,600 @ $21.61 (total cash paid ≈ $1,125,687).
• Shares sold: reported as multiple open‑market sales totaling ~56,894 shares for aggregate proceeds ≈ $11,904,247. Individual sale price ranges are given in the filing (F3–F8) and reported prices are weighted averages.
• Holdings after transaction: Filing excerpt does not state a single total; it notes that reported holdings include 43,514 restricted stock units (F2).
• Trading plan: Sales were made pursuant to a 10b5‑1 trading plan adopted May 22, 2026 (F1).
• Vesting note: Option vesting schedule described (1/48th monthly from Sept 1, 2022; F9).
• The filing shows derivative exercise and immediate disposition entries (cashless/overnight sale style), consistent with exercising options and selling shares the same day.

Context

• This is a routine insider exercise-and-sell executed under a 10b5‑1 plan, which commonly limits inference about the timing or motivation of sales. For retail investors, purchases by insiders can be stronger signals than planned sales; here the activity appears to be an option exercise followed by market sales.